Nonetheless, we should note that under some other conditions, e.g., in tumours with intact DNA damage repair systems or cell-cycle checkpoints, activation of ATR–CHK1 signalling would inhibit cell-cycle progression and elicit tumour suppressor functions to block tumour development. The gene discussed is ATR; the disease is neoplasm.